ProQR Therapeutics N.V. (PRQR) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	18.6M	15.3M	18.9M	6.5M	3.6M
Cost of Revenue	1.4M	2.6M	—	—	—
Gross Profit	17.1M	12.7M	18.9M	6.5M	3.6M
Operating Expenses
R&D Expense	45.9M	40.7M	36.4M	25.1M	50.9M
SG&A Expense	15.1M	15.1M	13.7M	16.2M	18.7M
General & Admin Expense	10.9M	15.1M	13.7M	16.2M	18.7M
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	(670.1K)	(941.1K)	(640.0K)	(3.0M)	(765.0K)
Total Operating Expenses	60.4M	54.8M	49.4M	38.4M	68.8M
Cost and Expenses	61.8M	57.4M	49.4M	38.4M	68.8M
Operating Income (EBIT)	(43.2M)	(42.2M)	(30.5M)	(31.9M)	(65.2M)
Non-Operating
Interest Income	697.2K	2.2M	3.3M	2.6M	106.0K
Interest Expense	—	866.4K	1.1M	1.2M	5.1M
Net Interest Income	697.2K	1.4M	2.2M	1.4M	(5.0M)
Other Non-Op Income/Expense	847.3K	1.7M	2.5M	4.0M	1.1M
Non-Operating Income (excl Interest)	(2.8M)	(2.5M)	(3.6M)	(5.2M)	(6.2M)
EBT (Pre-Tax Income)	(42.4M)	(40.5M)	(28.0M)	(27.8M)	(64.1M)
Income Tax Expense	26.4K	18.2K	(197.0K)	(78.0K)	96.0K
Bottom Line
Net Income	(42.4M)	(40.5M)	(27.8M)	(28.1M)	(64.4M)
Earnings from Cont. Ops	(42.4M)	(40.5M)	(27.8M)	(27.7M)	(64.2M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(42.4M)	(40.5M)	(27.8M)	(28.1M)	(64.4M)
Per Share
Basic EPS	($0.40)	($0.38)	($0.34)	($0.35)	($0.91)
Diluted EPS	($0.40)	($0.38)	($0.34)	($0.35)	($0.91)
Revenue Per Share	$0.17	$0.15	$0.23	$0.08	$0.05
Shares
Basic Shares Outstanding	110.0M	105.3M	81.7M	81.0M	71.6M
Diluted Shares Outstanding	110.0M	105.3M	81.7M	81.0M	71.6M
Profitability Metrics
EBITDA	(37.7M)	(37.0M)	(24.1M)	(24.1M)	(56.5M)
D&A	2.8M	2.6M	2.8M	2.5M	2.5M
EBIT	(40.5M)	(39.6M)	(26.9M)	(26.6M)	(59.0M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026